Cancer of endometrium and prolonged XXXX therapy.

@entity172 @entity1 @entity1204 @entity565 @entity1425 @entity189 @entity102 @entity9193 @entity2588
A causal link between prolonged @entity172 (E) therapy and @entity1204 is argued for in this report of a case who was treated with large amounts of estrogenic substances almost continuously for an 8-year period. In 1919 a 25-year-old @entity1 was admitted with @entity565 of 1-year duration. @entity565 onset had been very severe, requiring administration of @entity1425 every few hours and frequent hospital observation. In 1928, the @entity1 was amenorrheic for 8 months; in 1936, she experienced @entity2588 for 4 months. In 1937 ( @entity1 now 45 years old), the relationship between @entity2588 and increased severity of @entity565 was suspected. At this time, the @entity1 also complained of hot flashes and sweats. Treatment with estrogenic substances was begun in 1937 and continued through 1945. 3 unusual features were noted during therapy: 1) persistence of hot flashes; 2) persistence of high urine titers of follicle stimulating hormone (FSH) despite adequate E doses; and 3) absence of bleeding when E was temporarily withdrawn. By 1945, @entity1204 had been identified by vaginal smear and verified by biopsy. Because of the previous absence of respose of FSH to prolonged E therapy, Es were omitted for 4 weeks, and after this period the vaginal smear showed complete absence of intrinsic estrogenic stimulation, and the urine titer of FSH was high. E given for 10 days caused moderate pituitary inhibition. Determination of @entity9193 made before and after therapy was abnormally low. Except for the state of @entity102 and the continuous administration of @entity565 medication (chronic alarm reaction?), there is no explanation of @entity189 grade 2.
